🇺🇸 FDA
Patent

US 7566465

Artemisinins in the clinical and veterinary management of kinetoplastid infections

granted A61KA61K31/357A61K31/366

Quick answer

US patent 7566465 (Artemisinins in the clinical and veterinary management of kinetoplastid infections) held by The United States of America as represented by the Secretary of the Army expires Mon Jul 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Secretary of the Army
Grant date
Tue Jul 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/357, A61K31/366, A61K36/282, A61P